Potassium

 Your 2024 Veganuary Must-Have Superfood Pantry Staple

Retrieved on: 
Wednesday, January 3, 2024
Copper, Glycemic index, Vitamin K, Vitamin, Vegetable, Mineral, Potassium, Grain boundary strengthening, Taste, Nutrient, Health, Heart, Antioxidant, RDN, Manganese, Boron, Exercise

In recent years, there has been increased popularity in the adoption of plant-based consumption, especially beginning with the month-long commitment of Veganuary.

Key Points: 
  • In recent years, there has been increased popularity in the adoption of plant-based consumption, especially beginning with the month-long commitment of Veganuary.
  • As individuals begin to embark on this journey, California Prunes is the dried fruit superfood you should try integrating as a nutritional powerhouse and vital superfood pantry-staple that can boost your nutrition throughout the month and year ahead.
  • Registered Dietitian Antoine Beauchamp Lepage emphasizes, “adopting a plant-based diet can enhance your energy, focus, weight management, and overall well-being.
  • Not merely a plant-powered snack, California Prunes prove to be a dynamic source of nutrients crucial for any lifestyle.

Veganuary’s Expert Panel Determines: Purple Sweet Potato is the 2024 Vegetable of the Year

Retrieved on: 
Wednesday, January 3, 2024
Biophysical environment, Vegetable, Restaurant, Kroger, Potassium, Social media, Taste, YouGov, Netflix, Nature, Shopper, Antioxidant, Innovation, Vitamin A, Longevity, Creativity, Food delivery

To select 2024's Vegetable of the Year, the expert panel considered five main criteria: growing popularity, versatility, sustainability, health/nutrition, and affordability/accessibility.

Key Points: 
  • To select 2024's Vegetable of the Year, the expert panel considered five main criteria: growing popularity, versatility, sustainability, health/nutrition, and affordability/accessibility.
  • With these criteria in mind, the panel determined the purple sweet potato is the official 2024 Vegetable of the Year.
  • Veganuary’s 2024 Vegetable of the Year Panelists:
    "Ever since I heard about the purple sweet potato’s history in Japan for longevity, I’ve been excited about them!
  • Also, who doesn’t love a potato that can be used in sweet or savory dishes,” said Tabitha Brown, actor and Veganuary Vegetable of the Year panelist.

Eating Healthier, Improving Mental Health: How Dairy Can Help Achieve Your New Year’s Resolutions

Retrieved on: 
Tuesday, January 2, 2024
Mental, Meal, Electrolyte, Risk, Vitamin, Mental health, Mineral, Fracture, Milk, Potassium, Hand, Glass, Sodium, Diet, Nutrient, Health, Dairy product, Fatigue, Magnesium, Perspiration, Calcium, Inflammation, Snack, Breakfast, Cheese, New Year's, Dicarboxylic acid, Type 2 diabetes, Obesity, Osteoporosis, Bone density, Hunger, Dairy Farmers, Yogurt, Exercise

Here are six ways that dairy can help you achieve your health and wellness goals for a better you in 2024.

Key Points: 
  • Here are six ways that dairy can help you achieve your health and wellness goals for a better you in 2024.
  • Nutrient packed: Dairy products such as milk, cheese, and yogurt are loaded with essential nutrients like calcium, protein, vitamins, and minerals.
  • Energy and weight management: Because of dairy foods’ nutritional package, it’s a one-stop shop to help sustain energy.
  • Mental Health: Stress and mental health often go hand in hand and can impact your overall well-being.

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, INN, Risk, Leukopenia, Hypophosphatemia, Hypotension, Pneumonia, Potassium, Nausea, Cancer, Myenteric plexus, Infection, Anatomy, Cough, IIA, Multiple myeloma, Chills, Consciousness, Diarrhea, Fever, Fatigue, Bone marrow, ATC, Pharyngitis, Pain, Platelet, Disease, Nose, Edema, Neutrophil, Speech, Depression, Appetite, Writing, Lymphocyte, Safety, Water, Tachycardia, Anemia, Neurological disorder, Hypocalcemia, Sepsis, Hypokalemia, Patient, Medical Subject Headings, Febrile neutropenia, Lymphocytopenia, Cytokine release syndrome, International, Encephalopathy, Neutropenia, Blood, Language, Thrombocytopenia, Neurotoxicity, Select, Medicine, Vomiting, Upper respiratory tract infection, Headache, Hospital, BCMA, Confusion, European Medicines Agency, Cell, Medical device

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Intrepid Engages Pickering Energy Partners as Lithium Advisor

Retrieved on: 
Tuesday, December 12, 2023
Lithium, Potash, Intrepid, IPI, Intrepid Potash, Potassium, Executive, Magnesium, CO, PEP, Pond

Denver, CO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Intrepid Potash, Inc. ("Intrepid," "we," or "our") (NYSE:IPI) today announced it engaged Pickering Energy Partners LP (“Pickering” or “PEP”) to advise on maximizing the value of the lithium resource at its mine in Wendover, Utah.

Key Points: 
  • Denver, CO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Intrepid Potash, Inc. ("Intrepid," "we," or "our") (NYSE:IPI) today announced it engaged Pickering Energy Partners LP (“Pickering” or “PEP”) to advise on maximizing the value of the lithium resource at its mine in Wendover, Utah.
  • Pickering has established itself as a leader and trusted advisor in the energy space and we are excited to partner together and evaluate promising new direct lithium extraction (“DLE”) technologies to recover lithium from our brine and create value for Intrepid and our shareholders."
  • “The opportunity for Intrepid to develop its lithium resource is compelling as its existing potash operation and infrastructure provide a clear path to production in the rapidly growing lithium industry,” said Dan Pickering, Chief Investment Officer of PEP.
  • In addition to potash and salt, our brine resource also contains magnesium, lithium, and other associated minerals.

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Retrieved on: 
Tuesday, November 28, 2023
HIV-1, Risk, Heartburn, MOA, Enzyme inhibitor, Potassium, FDA, Magnesium, Nausea, PPI, Inflammation, Prescription, Esophagus, Bone fracture, Skin, Chills, Extrapyramidal system, Fever, Vitamin, Breast milk, Infection, Diarrhea, Helicobacter pylori, Indigestion, Bleeding, Disease, Muscle weakness, Tongue, Calcium, Acid, University, Human, Pharmacy, Clostridioides, Vonoprazan, Urine, Hip, B-12, Food, Polyp, Esophagitis, GERD, Chronic pain, Blood, Dizziness, Blister, Gastroesophageal reflux disease, Tablet, Vitamin B12, Scar, Patient, Wrist, Medicine, Seizure, HIV, Stomach, Lymph, Allergy, Clostridioides difficile, Rash, Weakness, Urinary tract infection, Hypoesthesia, Week, Myalgia, Spine, Spasm, Kidney, Face, Rilpivirine, Lansoprazole, Pharmaceutical industry

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.

Key Points: 
  • “We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.
  • “Erosive GERD is a highly prevalent condition affecting over 20 million people in the U.S.,3,4 many of whom experience troubling symptoms, including painful heartburn.
  • Phathom is offering programs for eligible patients who face coverage or affordability issues, including co-pay assistance for patients with commercial insurance.
  • for up to 6 months to maintain healing of Erosive Acid Reflux and for relief of heartburn related to Erosive Acid Reflux.

Standard Lithium Provides Comprehensive Results of Its Fully Optimized and Proven DLE Process

Retrieved on: 
Monday, November 20, 2023
Lithium, Dorado, Plant, DLE, Demonstration plant, Potassium, Magnesium, LSS, FRA, Calcium, Knowledge, SLI, Lithium chloride, Boron, Sodium

EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.

Key Points: 
  • EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.
  • Standard Lithium's Demonstration Plant is the only truly large-scale, continuously operating DLE plant in North America.
  • Both studies incorporate the LiPROTM LSS (DLE) process developed in collaboration with Koch Technology Solutions, LLC (“KTS”).
  • Lithium Recovery Efficiency: During a representative period of performance over July and August 2023, the LiPROTM LSS (DLE) process achieved an average lithium recovery of 96.1% from the continuous incoming brine flow.

Standard Lithium Provides Comprehensive Results of Its Fully Optimized and Proven DLE Process

Retrieved on: 
Monday, November 20, 2023
Lithium, Dorado, Plant, DLE, Demonstration plant, Potassium, Magnesium, LSS, FRA, Calcium, Knowledge, SLI, Lithium chloride, Boron, Sodium

EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.

Key Points: 
  • EL DORADO, Ark., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today shared detailed performance results from its Direct Lithium Extraction (DLE) process at its Demonstration Plant (Plant) near El Dorado, Arkansas.
  • Standard Lithium's Demonstration Plant is the only truly large-scale, continuously operating DLE plant in North America.
  • Both studies incorporate the LiPROTM LSS (DLE) process developed in collaboration with Koch Technology Solutions, LLC (“KTS”).
  • Lithium Recovery Efficiency: During a representative period of performance over July and August 2023, the LiPROTM LSS (DLE) process achieved an average lithium recovery of 96.1% from the continuous incoming brine flow.

I love Fruit & Veg from Europe: fruit and veg throughout Christmas and New Year

Retrieved on: 
Thursday, December 21, 2023
European Commission, Onion, Attention, Vegetable, Potassium, Diet, Nutrient, Health, Civil service commission, Tart, Anthocyanin, Digestion, Water, Antioxidant, Fruit, Hazelnut, New Year's Eve

The heroes of Christmas lunch and New Year's Eve dinner are seasonal fruit and vegetables.

Key Points: 
  • The heroes of Christmas lunch and New Year's Eve dinner are seasonal fruit and vegetables.
  • The aim is to promote the consumption of European fruit and vegetables, and their organic and PDO/PGI counterparts.
  • The I love Fruit & Veg from Europe project also suggests breaking with tradition:  eat dried fruit as a snack, and not at the end of a meal.
  • Season's Greetings from I Love Fruit & Veg from Europe.

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, FDA, Health, Pharmaceutical, MSD, Medicine, DSM-IV codes, PD-L1, NYSE, Potassium, Food, Progression-free survival, RECIST, Merck & Co., Head, Pneumonia, Blood transfusion, Dana–Farber Cancer Institute, Risk, Lymphocyte, Hypoxia, Everolimus, Bleeding, IMDC, Fatigue, Sepsis, Patient, Pregnancy, PFS, Effectiveness, Belzutifan, Week, VHL, VEGF, RCC, COVID-19, PD-1, Creatinine, TKI, ORR, Harvard Medical School, Death, Anemia, Fatal, Sodium, Hospital, Pleural effusion, HIV disease progression rates, MRK, Pharmaceutical industry, Birth control, Merck

Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.

Key Points: 
  • Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.
  • Patients could have received up to three prior treatment regimens and were required to have measurable disease per RECIST v1.1.
  • Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients.
  • Adverse reactions that required dose reduction in ≥1% of patients were hypoxia (5%) and anemia (3.2%).